Eldecalcitol and eldecalcitol soft capsules obtained clinical approval. Eldecalcitol is a new active vitamin D3 derivative used to treat osteoporosis after alfacalcidol. It is better than alfacalcidol in improving bone mineral density and bone strength. With China entering the aged society, osteoporosis has become an increasingly serious public health problem. There are about 90 million osteoporosis patients in China. According to the statistics of the International Osteoporosis Foundation, 286 million people will suffer from low bone density or osteoporosis in China by 2020 alone. It is estimated that by 2050, the number of osteoporosis patients will rise to 533 million. The demand for osteoporosis drugs in the market will be increasing. After being listed in Japan, eldecalcitol will gradually replace calcitriol and alfacalcidol with its characteristics of good curative effect, high safety and stable quality. Eldecalcitol has not yet been listed in domestic market, with small competition, outstanding advantages, no administrative protection and patent protection, and no legal disputes. Therefore, eldecalcitol will have good market prospects.